Despite its history as the “nation’s medicine chest,” New Jersey’s biopharma industry is lagging some other states like California and Massachusetts. But the situation can be turned around if the state government, academia, and the industry itself work together on a focused strategy to better fund and support the sector.
That was the message highlighted by BioNJ, the trade association for the state’s life-sciences industry, which released a white paper Thursday that assesses the state of the sector and outlines strategies for Gov.-elect Phil Murphy and other Garden State leaders to use in improving New Jersey’s competitiveness. (Murphy’s team did not respond to a request for comment.)
